Plante Moran Financial Advisors’s Galectin Therapeutics GALT Stock Holding History

Plante Moran Financial Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,798	Closed	-$7K	–	1036
2021 Q3	$7K	Hold	1,798	–	–	﹤0.01%	741
2021 Q2	$6K	Buy	1,798 +100	+6%	+$356	﹤0.01%	754
2021 Q1	$4K	Hold	1,698	–	–	﹤0.01%	807
2020 Q4	$4K	Buy	1,698 +300	+21%	+$787	﹤0.01%	715
2020 Q3	$4K	Hold	1,398	–	–	﹤0.01%	712
2020 Q2	$4K	Hold	1,398	–	–	﹤0.01%	615
2020 Q1	$3K	Buy	1,398 +199	+17%	+$484	﹤0.01%	617
2019 Q4	$3K	Hold	1,199	–	–	﹤0.01%	659
2019 Q3	$4K	Sell	1,199 -600	-33%	-$2.17K	﹤0.01%	714
2019 Q2	$7K	Buy	+1,799	New	+$7.79K	﹤0.01%	603

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Plante Moran Financial Advisors's GALT Position: Q4 2021 in Review

Plante Moran Financial Advisors sold out of Galectin Therapeutics (GALT) in Q4 2021, closing a stake of 1,798 shares — an estimated $7K sold.

Plante Moran Financial Advisors first reported a position in GALT in Q2 2019 and held it in 10 quarters. The position peaked at $7K in Q3 2021. 55 funds tracked by Wall St. Rank hold GALT as of Q4 2021.

Plante Moran Financial Advisors reported no remaining Galectin Therapeutics position as of Q4 2021 after selling out during the quarter.
Plante Moran Financial Advisors sold 1,798 Galectin Therapeutics shares in Q4 2021, an estimated $7K.
Plante Moran Financial Advisors first reported a position in Galectin Therapeutics in Q2 2019 and held it in 10 quarters.
Plante Moran Financial Advisors's Galectin Therapeutics position peaked at $7K in Q3 2021.
55 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2021.

Based on Plante Moran Financial Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.